PHG - Philips Biodesix team up to advance early lung cancer diagnosis

• Royal Philips ( NYSE: PHG ) said it is incorporating the results of Biodesix's ( NASDAQ: BDSX ) blood-based lung nodule risk assessment testing Nodify Lung into its patient management system Lung Cancer Orchestrator.
• Amsterdam-based Philips said including proteomics data — along with radiologic and patient history data which is currently used to decide treatment decisions — can help create diagnostic efficiency for cancer care centers in managing lung nodule cases.
• Philips noted that Lung Cancer Orchestrator is a patient management system for CT lung cancer screening programs and incidental lung nodule findings which keeps track of patients appointments, diagnostics, test results, and and clinical decisions.
• "By incorporating Biodesix's Nodify Lung testing, we take another step in leveraging integrated diagnostics from imaging, genomics, and now proteomic results from a simple blood draw to address key moments in the lung cancer patient journey, support care team decision-making, and help health systems learn from their practice patterns in a dashboard view," said Louis Culot, general manager Oncology Informatics and Genomics at Philips ( PHG ).

For further details see: